3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
17
Burkitt Lymphoma
16
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
4
Recurrence
3
Lymphoma, Large B-Cell, Diffuse
2
Leukemia
2
Philadelphia Chromosome
1
Neoplasm, Residual
1
Lymphoma, B-Cell
1
Lymphoma
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Hematologic Neoplasms
1
Blast Crisis
1
Interventions
Imatinib Mesylate
5
Dasatinib
4
Vincristine
3
Methotrexate
3
Dexamethasone
3
Cytarabine
3
peginterferon alfa-2a
2
Prednisone
2
Daunorubicin
2
Cyclophosphamide
2
Azacitidine
2
venetoclax
1
thymoglobulin
1
ponatinib
1
olverembatinib
1
flumatinib
1
fludarabine phosphate
1
fludarabine
1
blinatumomab
1
Whole-Body Irradiation
1
Tyrosine Kinase Inhibitors
1
Tacrolimus
1
Rituximab
1
Prednisolone
1
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
1
Mycophenolic Acid
1
Mitoxantrone
1
Mercaptopurine
1
Melphalan
1
Interferons
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Philadelphia Chromosome
×
Inotuzumab Ozogamicin
×
Clear all
NCT03249870
2023-09-06
EWALL-INO
Versailles Hospital
Phase 2
Unknown
130 enrolled